Saturday 17 October 2026
Export MDGL’s income statement to Excel — free account
Madrigal Pharmaceuticals, Inc.
MDGL Healthcare Biotechnology
Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024. In the quarter to June 2026, revenue grew 71.2%, EPS fell 32.9%, free cash flow grew 140.5% and total debt rose 187.9%, each against the same quarter a year earlier.
449.74
10.07
−2.19%
Follow MDGL
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | — | — | — | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | — | — | — | — | — | 10.85 | 10.48 |
P/S ratio |
— | — | — | — | — | — | — | — | 0.00 | 13.63 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | — | — | — | (0.66) | (1.18) |
P/FCF ratio |
— | — | — | — | — | — | — | — | 0.00 | 0.00 |
Beneish M-Score |
— | — | — | — | — | — | — | — | — | 0.50 |
P/Operating CF |
— | — | — | — | — | — | — | — | (62.82) | (97.89) |
P/B ratio |
— | — | — | — | — | — | — | — | 8.70 | 21.68 |
Price to Tangible BV |
— | — | — | — | — | — | — | — | 8.76 | 21.95 |
EV/Sales |
— | — | — | — | — | — | — | — | 0.00 | 12.95 |
EV/EBITDA |
— | — | — | — | — | — | — | — | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | — | — | — | — | (12.62) | (65.50) |
EV/FCF |
— | — | — | — | — | — | — | — | (12.45) | (64.00) |
Quick Ratio |
8.44 | 19.05 | 57.29 | 17.47 | 6.10 | 3.52 | 3.10 | 5.35 | 5.82 | 3.62 |
Current Ratio |
8.58 | 19.10 | 57.46 | 17.52 | 6.13 | 3.54 | 3.12 | 5.38 | 6.10 | 4.01 |
Net Debt/EBITDA |
1.61 | 5.99 | 11.92 | 4.62 | 1.38 | 1.12 | 1.06 | 1.37 | 1.64 | 2.21 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.08% | 0.16% | 0.14% | 13.59% | 18.03% | 11.28% | 26.98% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.25 | 0.28 | 0.16 | 0.56 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.21 | 0.83 |
Operating CF/Net income |
0.67 | 0.72 | 0.78 | 0.50 | 0.78 | 0.76 | 0.76 | 0.87 | 0.98 | 0.66 |
Capex/Depreciation |
3,475.00 | (1.62) | (0.23) | (1.54) | (0.71) | (0.52) | (0.17) | (0.50) | (2.32) | (0.55) |
Interest Coverage |
(20.79) | (57.46) | (5.30) | (8.61) | (47.74) | — | (74.06) | (29.93) | (33.94) | (13.45) |
| 422.09% | (28.49%) | (9.95%) | (18.79%) | (61.61%) | (110.92%) | (150.12%) | (123.98%) | (80.35%) | (42.49%) | |
| (126.95%) | (26.68%) | (9.68%) | (18.10%) | (55.48%) | (86.32%) | (92.89%) | (74.49%) | (55.37%) | (25.05%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(72.47%) | (17.09%) | (6.88%) | (20.17%) | (84.39%) | (123.58%) | (120.02%) | (71.81%) | (53.81%) | (30.77%) |
Average Days of Receivables |
— | — | — | — | — | — | — | — | 109.06 | 51.21 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 131.41% | 40.54% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 241.52% | 84.91% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 44.35% | 10.24% |
Graham Net Nets |
— | — | — | — | — | — | — | — | 0.11 | 0.05 |
Graham Number |
— | — | — | — | — | — | — | — | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | — | — | — | — | (7.17%) | (2.02%) |
Free Cash Flow Yield |
— | — | — | — | — | — | — | — | (7.04%) | (1.48%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.47 | 42.72 |
Operating CF per Share |
(3.38) | (1.82) | (1.72) | (2.70) | (10.20) | (11.12) | (13.12) | (17.35) | (21.42) | (8.45) |
Capex per Share |
0.13 | (0.01) | 0.00 | (0.01) | (0.02) | (0.01) | (0.01) | (0.08) | (0.30) | (0.15) |
Free Cash Flow per Share |
(3.25) | (1.83) | (1.73) | (2.71) | (10.22) | (11.14) | (13.13) | (17.43) | (21.72) | (8.60) |
Cash per Share |
7.78 | 15.64 | 32.69 | 28.52 | 18.40 | 16.35 | 20.94 | 33.93 | 43.78 | 44.07 |
Shareholders Equity per Share |
7.00 | 14.88 | 32.24 | 27.06 | 15.54 | 11.86 | 11.52 | 21.69 | 35.46 | 26.87 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
7.00 | 14.88 | 32.24 | 27.06 | 15.54 | 11.86 | 11.52 | 21.69 | 35.46 | 26.87 |
Free Cash Flow |
(16.91) | (22.44) | (25.53) | (41.80) | (157.89) | (184.13) | (225.07) | (325.71) | (462.03) | (193.02) |
Working Capital |
36.41 | 181.96 | 476.76 | 415.07 | 238.61 | 194.85 | 245.48 | 518.73 | 863.65 | 935.48 |
Capital Expenditures |
0.70 | (0.12) | (0.02) | (0.17) | (0.33) | (0.21) | (0.22) | (1.48) | (6.46) | (3.47) |
Net Current Asset Value |
36.41 | 181.96 | 476.76 | 414.71 | 238.14 | 194.46 | 196.19 | 402.07 | 745.06 | 588.87 |
EV/EBIT |
— | — | — | — | — | — | — | — | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 |
Price to Operating Income |
— | — | — | — | — | — | — | — | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.07 | 0.26 | 0.42 | 0.09 | 0.45 | 0.48 | 2.10 | 1.89 | 1.27 | 4.22 |
Cash ROIC |
(21.99%) | (6.00%) | (2.66%) | (4.88%) | (30.10%) | (39.44%) | (37.17%) | (28.20%) | (25.62%) | (9.99%) |
Accounts Receivable Turnover |
— | — | — | — | — | — | — | — | 6.69 | 10.18 |
Accounts Payable Turnover |
0.00 | 0.06 | 0.04 | 0.06 | 0.43 | 0.04 | 0.02 | 0.00 | 0.17 | 1.21 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 1.03 |
Average Days of Payables |
1,390,650.00 | 9,143.96 | 9,455.78 | 3,839.02 | 788.12 | 19,268.40 | 18,625.94 | 0.00 | 2,553.13 | 317.74 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 1,995.00 | 486.52 |
Average Receivables |
— | — | — | — | — | — | — | — | 26.91 | 94.15 |
Average Payables |
0.43 | 1.35 | 2.21 | 1.83 | 1.10 | 11.20 | 22.61 | 25.94 | 35.82 | 46.24 |
Average Inventory |
— | — | — | — | — | — | — | — | — | 54.45 |
Average Assets |
20.79 | 116.76 | 338.87 | 463.74 | 364.53 | 280.16 | 317.95 | 501.56 | 841.40 | 1,150.92 |
Average Common Equity |
(6.25) | 109.33 | 329.62 | 446.77 | 328.27 | 218.04 | 196.75 | 301.36 | 579.86 | 678.54 |
Columns are period end dates